AIM
ABBV icon

Acropolis Investment Management’s AbbVie ABBV Stock Holding History

Acropolis Investment Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.77M Buy
7,039
+51
+0.7% +$11K 0.07% 89
2026
Q1 		$1.52M Sell
6,988
-50
-0.7% -$11.1K 0.07% 93
2025
Q4 		$1.61M Buy
7,038
+60
+0.9% +$13.7K 0.07% 88
2025
Q3 		$1.3M Buy
6,978
+3,746
+116% +$763K 0.07% 98
2025
Q2 		$600K Sell
3,232
-262
-7% -$48.7K 0.03% 140
2025
Q1 		$732K Buy
3,494
+98
+3% +$19.1K 0.04% 116
2024
Q4 		$604K Sell
3,396
-876
-21% -$161K 0.04% 138
2024
Q3 		$844K Buy
4,272
+394
+10% +$73.5K 0.05% 111
2024
Q2 		$665K Sell
3,878
-1,685
-30% -$279K 0.04% 124
2024
Q1 		$1.01M Sell
5,563
-2
-0% -$345 0.07% 95
2023
Q4 		$862K Buy
5,565
+74
+1% +$10.8K 0.06% 101
2023
Q3 		$819K Buy
5,491
+2,172
+65% +$319K 0.06% 100
2023
Q2 		$447K Buy
3,319
+1,013
+44% +$149K 0.04% 145
2023
Q1 		$367K Sell
2,306
-10
-0.4% -$1.53K 0.03% 160
2022
Q4 		$374K Sell
2,316
-36
-2% -$5.52K 0.03% 151
2022
Q3 		$316K Sell
2,352
-100
-4% -$14.3K 0.03% 155
2022
Q2 		$375K Buy
2,452
+33
+1% +$5.04K 0.04% 146
2022
Q1 		$392K Hold
2,419
– – 0.04% 140
2021
Q4 		$327K Buy
2,419
+95
+4% +$11.2K 0.03% 151
2021
Q3 		$249K Hold
2,324
– – 0.03% 161
2021
Q2 		$262K Hold
2,324
– – 0.03% 158
2021
Q1 		$251K Buy
2,324
+185
+9% +$19.8K 0.03% 156
2020
Q4 		$229K Sell
2,139
-200
-9% -$19.2K 0.03% 157
2020
Q3 		$205K Buy
2,339
+366
+19% +$34.5K 0.03% 154
2020
Q2 		$194K Sell
1,973
-24
-1% -$2.11K 0.03% 152
2020
Q1 		$152K Sell
1,997
-180
-8% -$15.3K 0.02% 157
2019
Q4 		$186K Buy
2,177
+76
+4% +$6.31K 0.03% 134
2019
Q3 		$159K Buy
2,101
+5
+0.2% +$343 0.02% 141
2019
Q2 		$152K Sell
2,096
-194
-8% -$15.2K 0.02% 125
2019
Q1 		$185K Buy
2,290
+4
+0.2% +$327 0.03% 121
2018
Q4 		$211K Buy
2,286
+2
+0.1% +$176 0.04% 113
2018
Q3 		$216K Sell
2,284
-52
-2% -$4.93K 0.03% 113
2018
Q2 		$216K Buy
2,336
+303
+15% +$29.6K 0.04% 113
2018
Q1 		$192K Buy
2,033
+178
+10% +$19.6K 0.03% 119
2017
Q4 		$179K Buy
1,855
+211
+13% +$19.9K 0.03% 124
2017
Q3 		$146K Buy
1,644
+183
+13% +$13.9K 0.02% 128
2017
Q2 		$106K Buy
+1,461
New +$98.2K 0.02% 143
2016
Q3 		– Sell
-1,711
Closed -$106K – 135
2016
Q2 		$106K Buy
+1,711
New +$104K 0.02% 132
2015
Q1 		– Sell
-2,145
Closed -$140K – 147
2014
Q4 		$140K Sell
2,145
-588
-22% -$37.1K 0.03% 133
2014
Q3 		$158K Buy
2,733
+433
+19% +$24K 0.03% 126
2014
Q2 		$130K Hold
2,300
– – 0.03% 133
2014
Q1 		$118K Hold
2,300
– – 0.02% 126
2013
Q4 		$121K Hold
2,300
– – 0.03% 119
2013
Q3 		$103K Buy
+2,300
New +$102K 0.02% 125

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Acropolis Investment Management's ABBV Position: Q2 2026 in Review

Acropolis Investment Management increased its AbbVie (ABBV) stake by 0.73% in Q2 2026, buying an estimated $11K and bringing the position to 7,039 shares worth $1.77M. The position accounts for 0.07% of the portfolio, ranked #89.

Acropolis Investment Management first reported a position in ABBV in Q3 2013 and has held it in 44 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Acropolis Investment Management held 7,039 shares of AbbVie worth $1.77M as of Q2 2026.
  • Acropolis Investment Management bought 51 AbbVie shares in Q2 2026, an estimated $11K.
  • AbbVie made up 0.07% of Acropolis Investment Management's portfolio in Q2 2026, its #89 holding.
  • Acropolis Investment Management first reported a position in AbbVie in Q3 2013 and has held it in 44 quarters since.
  • 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Acropolis Investment Management's 13F filing for Q2 2026, filed 15 Jul 2026.